Consistent with this, Xu et al. showed that patients with low Mfn2 levels had poorer prognoses, indicating more aggressive tumors, and they demonstrated that Mfn2 loss enhanced tumor growth in breast and lung cancer xenograft systems [86]. This evidence concerns the gene MFN2 and lung carcinoma.